ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MYL Mylan NV

15.855
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Mylan NV NASDAQ:MYL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.855 15.71 15.90 0 01:00:00

Keller Rohrback L.L.P. Investigates EpiPen Overcharges

07/10/2016 12:47am

Business Wire


Mylan NV (NASDAQ:MYL)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Mylan NV Charts.

Attorney Advertising. Mylan N.V. (NASDAQ: MYL) may be significantly overcharging patients for its EpiPen allergy shot. Since Mylan acquired the drug in 2007, the price has increased six-fold, from $100 to $600 for two doses. Yet Mylan pays only $34.50 per pen.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161006006550/en/

Since Mylan acquired the drug in 2007, the price has increased six-fold, from $100 to $600 for two doses. Yet Mylan pays only $34.50 per pen. (Photo: Business Wire)

The EpiPen is a small device that automatically injects a dose of the drug epinephrine into the thigh to counter life-threatening reactions to allergens such as peanuts, shellfish and bee stings. According to National Food Allergy Guidelines, a delay in administering epinephrine can be life-threatening.

Mylan claims the price increase can be explained by more than $1 billion it has invested to improve the EpiPen. In 2009 Mylan launched an upgraded version of the EpiPen; however, recent independent studies show there is little change to the design of the pen. PA Consulting Group, a UK-based technology consulting firm, found that “it’s the same core device that’s been used for some time.” The firm estimates the redesign may have only cost Mylan several million dollars. In 2015, the EpiPen brought in over $1 billion in sales for the company.

If you or someone you know has purchased an EpiPen since 2007, please contact attorneys Michael Meredith or Gretchen Freeman Cappio. Call 800-776-6044 or email consumer@kellerrohrback.com.

Keller Rohrback L.L.P. has decades of experience helping consumers and insureds fight back against fraud and abuse. Keller Rohrback L.L.P. serves as lead and co-lead counsel in class action lawsuits throughout the country. With offices in New York, Seattle, Phoenix, Ronan, Oakland, and Santa Barbara, our Complex Litigation Group is proud to offer its expertise to clients nationwide. Our trial lawyers have obtained judgments and settlements on behalf of clients in excess of seven billion dollars.

Attorney Advertising. Prior results do not guarantee a similar outcome. Not licensed to practice law in all states. Please refer to our website for details.

Keller Rohrback L.L.P.Michael Meredith or Gretchen Freeman Cappio, Attorneys800-776-60441201 Third Avenue, Suite 3200Seattle, WA 98101consumer@kellerrohrback.comhttp://www.krcomplexlit.com

1 Year Mylan NV Chart

1 Year Mylan NV Chart

1 Month Mylan NV Chart

1 Month Mylan NV Chart

Your Recent History

Delayed Upgrade Clock